Welcome to BioSeeker Group!

Triple Analysis: Leukemia, Lymphoma and Angiogenesis

Additional Information

Published Date Jan 30, 2012
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3805
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Leukemia, Lymphoma and Angiogenesis in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in both Leukemia and Lymphoma and by the mechanism/target/effect of Angiogenesis.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Leukemia, Lymphoma and Angiogenesis.

    To find out more about Triple Analysis: Leukemia, Lymphoma and Angiogenesis, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Leukemia, Lymphoma and Angiogenesis is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in both Leukemia and Lymphoma and by the mechanism/target/effect of Angiogenesis. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Leukemia
The leukemia report part comprises defined and up to date development strategies for 313 leukemia drugs within the portfolio of 186 investigators, from Ceased to Marketed. This part extensively analyses their 204 identified drug targets, organized into 193 drug target strategies, and assesses them in eight different compound strategies and and eight subindications of leukemia.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market

Part II: Lymphoma
The lymphoma report part comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 154 investigators, from Ceased to Marketed. This part extensively analyses their 181 identified drug targets, organized into 173 drug target strategies, and assesses them in eight different compound strategies and and five subindications of lymphoma.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market

Part III: Angiogenesis
The angiogenesis affecting cancer drug report part comprises defined and up to date development strategies for 252 drugs in oncology within the portfolio of 151 companies world-wide, from Ceased to Marketed. The report extensively analyses their 177 identified drug targets, organized into 170 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Leukemia
5.1 The Scope of this Report 29
6 Consider the Therapeutic Target Among Leukemia Drugs for the Highest Therapeutic Outcome and Return on Investment (204 Drug Targets) 33-443
7 Emerging New Products to Established Ones: Drug Target Strategies of Leukemia Drugs by their Highest Stage of Development (193 Drug Target Strategies and 313 Leukemia Drugs) 444-727
8 Compound Strategies at Work: Competitive Benchmarking of Leukemia Drugs by Compound Strategy (8 Compound Strategies) 679-728
9 Selecting Subindication for Leukemia Drugs (8 Subindications of Leukemia) 729-762
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Leukemia Drug Pipeline by Investigator (186 Companies) 763-1,129
11 Disclaimer 1130
12 Drug Index 1131
13 Company Index 1140
Figures: Includes 6 Figures
Tables: Includes 253 Tables
Total Number of Pages: 1,147

Part II: Lymphoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Lymphoma Drugs for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 30-387
7 Emerging New Products to Established Ones: Drug Target Strategies of Lymphoma Drugs by their Highest Stage of Development (173 Drug Target Strategies and 282 Lymphoma Drugs) 388-596
8 Compound Strategies at Work: Competitive Benchmarking of Lymphoma Drugs by Compound Strategy (8 Compound Strategies) 597-636
9 Selecting Subindication for Lymphoma Drugs (Five Subindications of Lymphoma) 637-657
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lymphoma Drug Pipeline by Investigator (152 Companies) 658-938
11 Disclaimer 939
12 Drug Index 940
13 Company Index 948
Figures: Includes 6 Figures
Tables: Includes 222 Tables
Total Number of Pages: 954

Part III: Angiogenesis
5.1 The Scope of this Report 37
6 Consider the Therapeutic Target Among Angiogenesis Affecting Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (177 Drug Targets) 41-421
7 Emerging New Products to Established Ones: Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology by their Highest Stage of Development (170 Drug Target Strategies and 252 Drugs) 424-666
8 Compound Strategies at Work: Competitive Benchmarking of Angiogenesis Affecting Cancer Drugs by Compound Strategy (7 Compound Strategies) 667-709
9 Selecting Indication for Angiogenesis Affecting Drugs in Oncology (70 Cancer Indications) 710-848
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (151 Investigators and 252 Drugs) 849-1685
12 Drug Index 1687
13 Company Index 1697
Figures: Includes 7 Figures
Tables: Includes 310 Tables
Total Number of Pages: 1,704

This Report Includes the Following Companies:
3M Pharmaceuticals
4SC
Abbott
Abiogen
Acceleron Pharma
Access
Actinium Pharmaceuticals
Active Biotech
Adherex
Advantagene
Advaxis
Advenchen
AEgera
AEterna Zentaris
Affimed Therapeutics
Agennix
Agenus
Aida Pharmaceuticals
Alexion
Alfa Wassermann
Alfacell
Allos Therapeutics
Alnylam
Altor BioScience
Ambit Biosciences
Ambrilia Biopharma
Amgen
Amphora
Angiogen
Angiogenex
Angstrom Pharmaceuticals
Ansaris
Antisoma
Apricus Biosciences
Arana Therapeutics
Arca biopharma
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Asahi Kasei Pharma
Ascenta Therapeutics
Astellas
Astex Therapeutics
AstraZeneca
Attenuon
Austrianova
AVEO
Bayer
Benitec
Bio-Path Holdings
BioAlliance Pharma
BioAxone
Biocad
Biocon
BioCryst Pharmaceuticals
Bioenvision
Biogen Idec
Biolex
BioSante
Bioton
Boehringer Ingelheim
Bolder BioTechnology
Borean Pharma
Bristol-Myers Squibb
BTG
Callisto Pharmaceuticals
Cancer Research Technology
CDG Therapeutics
Celator Pharmaceuticals
Celecure
Celera
Celgene
Cell Therapeutics
CellCeutix
Celldex Therapeutics
Cellmid
Celltrion
Cephalon
ChemoCentryx
Chemokine Therapeutics
China Sky One Medical
Choongwae
Circadian Technologies
CJ Corp
Clavis Pharma
Cornerstone Pharmaceuticals
CSL
Cue Biotech
Curacyte
CureTech
Curis
Cyclacel
Cylene Pharmaceuticals
CytImmune Sciences
Cytochroma
Cytokinetics
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Deciphera Pharmaceuticals
Dendreon
DiaMedica
Dong-A
Dr Reddy’s
Dyax
Dynavax Technologies
Eisai
Eleos
Eli Lilly
Emergent BioSolutions
EntreMed
Enzon
EpiCept
Epizyme
Erimos
Esperance Pharmaceuticals
Exelixis
ExonHit Therapeutics
Favrille
Five Prime Therapeutics
Forma Therapeutics
GammaCan
Gemin X Biotechnologies
Genencor
Genentech
Genmab
GenPat77
Genta
Genzyme
Geron
Gilead Sciences
GlaxoSmithKline
GlycoGenesys
GlycoMimetics
Green Cross
Hanmi
Hayashibara
Heber Biotec
HemaQuest
Hoffmann-La Roche
Human Genome Sciences
Hy BioPharma
Idera Pharmaceuticals
IDM Pharma
IGF Oncology
IkerChem
ImClone Systems
Immune Pharmaceuticals
Immunocore
ImmunoGen
Immunomedics
ImmuPharma
Incyte Corporation
InDex Pharmaceuticals
Inex
Innate Pharma
InNexus Biotechnology
Innovive
Inovio
Insys Therapeutics
Intas Biopharmaceuticals
Intracel
Introgen Therapeutics
Isis Pharmaceuticals
Italfarmaco
Johnson & Johnson
KAI Pharmaceuticals
KaloBios
Kanisa
Karus Therapeutics
Kinex
Kirin Pharma
Kissei
Kringle Pharma
Kyowa Hakko Kirin
Lee’s Pharmaceutical
Leo
LFB Biotechnologies
LG Life Sciences
Ligand
Lorus Therapeutics
MacroGenics
MAT Biopharma
MaxCyte
MaxoCore Pharmaceuticals
Meda
MediGene
MedImmune
Memgen
Merck & Co
Merck KGaA
Mersana Therapeutics
MethylGene
Micromet
MolMed
Mologen
Morvus Technology
Nektar Therapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
NewSouth Innovations
NIH
Nippon Shinyaku
Non-industrial source
Novartis
Novelix
Novogen
Noxxon
Nycomed Pharma
Oasmia
Onconova
OncoTherapy Science
Oncothyreon
OSI Pharmaceuticals
Otsuka
Oxford BioMedica
OXiGENE
Pepscan Therapeutics
PepTx
Peregrine Pharmaceuticals
Pfizer
Pharmacopeia
Pharmacyclics
PharmaMar
Pharminox
Philogen
PhiloGene
PIERIS Proteolab
Pierre Fabre
Piramal
Plexxikon
Portola Pharmaceuticals
Prochon Biotech
Progen
ProMetic Life Sciences
ProNAi Therapeutics
Protein Sciences
Protgen
PTC Therapeutics
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Reliance Life Sciences
Rexahn
Rigel
Sangamo BioSciences
Sanofi
Sanofi-Aventis
Santaris Pharma
Sareum
SBI Biotech
SBIO
Scancell
SciClone Pharmaceuticals
Seattle Genetics
Selvita
Semafore Pharmaceuticals
Sepal Pharma
Servier
Shenogen
Shionogi
Shire
Sidus
Simcere Pharmaceuticals
Southern Research Institute
Spear Therapeutics
Spirogen
SRI International
Stainwei Biotech
Stemline Therapeutics
SuperGen
SuppreMol
Swedish Orphan Biovitrum
Switch Pharma
SymBio Pharmaceuticals
Symbiotec
Synageva BioPharma
SynDevRx
Synta Pharmaceuticals
Syntrix
Taiho
Takeda
Talon Therapeutics
Tapestry Pharmaceuticals
Targa Therapeutics
TargeGen
Tau Therapeutics
TeGenero
Tekmira Pharmaceuticals
Telik
TetraLogic Pharmaceuticals
Teva
ThromboGenics
Tigris Pharmaceuticals
Titan Pharmaceuticals
ToolGen
TopoTarget
Tracon Pharmaceuticals
Transgene
Trion Pharma
UCB
Vaccinex
Valeant
VBL Therapeutics
VentiRx Pharmaceuticals
Vertex Pharmaceuticals
Wilex
Vion Pharmaceuticals
VioQuest Pharmaceuticals
XBiotech
Xencor
Xerion
Yakult Honsha
Yamasa Corporation
Zenotech
Zenyaku Kogyo
A Shortlist of Drugs Included are:
131I-tositumomab
A6
ABT-510
aflibercept
alemtuzumab
AMG-386
amonafide malate
amrubicin hydrochloride
amsacrine
Angiozyme
apatinib
ARQ-197
atrasentan
axitinib
barasertib
belinostat
bevacizumab
bexarotene
BIBF-1120
bisantrene
BMS-690514
bortezomib
bosutinib
brentuximab vedotin
brivanib alaninate
cediranib
cilengitide
cladribine
clofarabine
CSF-GM
cytarabine ocfosfate
cytarabine, injectable
dasatinib
daunorubicin
decitabine
denileukin diftitox
DI-17E6
dovitinib lactate
E-7820
elacytarabine
elliptinium acetate
endostatin
ENMD-2076
enocitabine
enzastaurin hydrochloride
epirubicin
everolimus
Exherin
foretinib
fosbretabulin tromethamine
galiximab
gemtuzumab ozogamicin
GliaAtak
GT-111
HBP-347
histamine dihydrochloride
ibritumomab tiuxetan
icrucumab
idarubicin
imatinib mesilate
inotuzumab ozogamicin
interferon
interferon (alpha-N1)
interferon (alpha)
interferon (alpha2)
interferon (alpha2a)
interferon (alpha2b)
interferon (alpha2c)
interferon (gamma)
interferon alfa-2b
interferon alpha-2b
intetumumab
IPP-204106
irinotecan hydrochloride
JI-101
lenvatinib
lestaurtinib
leukemia vaccine
linifanib
lumiliximab
LY-2275796
MGCD-265
midostaurin
mitoxantrone
motesanib diphosphate
muparfostat (IV)
NGR-TNF
nilotinib
obinutuzumab
oblimersen sodium
ofatumumab
ON-01910
OTS-102
paclitaxel
PancAtak
panobinostat
pazopanib hydrochloride
PCI-27483
pegdinetanib
peginterferon alfa-2b
pentostatin
PF-4856884
pixantrone
plitidepsin
ponatinib
pralatrexate
ProstAtak
PTC-299
RAF-265
ramucirumab
razoxane
Reditux
regorafenib
rhIFN-alpha
ridaforolimus
rituximab
romidepsin
sirolimus
sobuzoxane
sorafenib tosylate
SU-6668
sunitinib malate
talactoferrin alfa
tamibarotene
TAS-102
tasquinimod
TB-403
telatinib
temsirolimus
Tenarad
teniposide
thymalfasin
tipifarnib
tivozanib
TRC-105
vandetanib
vismodegib
volociximab
vosaroxin
XL-184
XL-647
zanolimumab
zorubicin

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Leukemia, Lymphoma and Angiogenesis.
    To find out more about Triple Analysis: Leukemia, Lymphoma and Angiogenesis, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Leukemia, Lymphoma and Angiogenesis is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Prostate Cancer, Protein Kinase Inhibitors and Antibodies
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Prostate Cancer), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Antibodies). Learn More


Triple Analysis: Breast Cancer, Melanoma and Cancer Vaccines
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Melanoma and by the mechanism/target/effect of Cancer Vaccines. Learn More

Other selected research from the 'Oncology' category:


Cellular Therapy in Oncology Drug Pipeline Update
BioSeeker Group have identified 164 companies plus partners who are today developing 272 cellular therapy drugs in 577 developmental projects in cancer across 92 different targets. In addition, there are 7 suspended drugs and another 66 drugs where development has been ceased. Learn More


Triple Analysis: Colorectal Cancer, Melanoma and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Melanoma and by the mechanism/target/effect of Protein Kinase Inhibitors. Learn More